Literature DB >> 12137975

GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.

Ayhan Bozkurt1, Erik Näslund, Jens Juul Holst, Per M Hellström.   

Abstract

Small bowel motility was studied in rats at increasing (1-20 pmol/kg/min) intravenous doses of either glucagon-like peptide-1 (GLP-1) or glucagon-like peptide-2 (GLP-2) alone, or in combination in the fasted and fed state. There was a dose-dependent inhibitory action of GLP-1 on the migrating myoelectric complex (MMC), where the dose of 5 pmol/kg/min induced an increased MMC cycle length. No effect was seen with GLP-2 alone, but the combination of GLP-1 and GLP-2 induced a more pronounced inhibitory effect, with significant increase of the MMC cycle length from a dose of 2 pmol/kg/min. During fed motility, infusion of GLP-1 resulted in an inhibition of spiking activity compared to control. In contrast, infusion of GLP-2 only numerically increased spiking activity compared to control, while the combination of GLP-1 and GLP-2 resulted in no change compared to control. In summary, this study demonstrates an additive effect of peripheral administration of GLP-1 and GLP-2 on fasted small bowel motility. In the fed state, GLP-1 and GLP-2 seem to display counter-balancing effects on motility of the small intestine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12137975     DOI: 10.1016/s0167-0115(02)00095-2

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Marie Langmach Wegeberg; Christian Stevns Hansen; Adam D Farmer; Jesper Scott Karmisholt; Asbjorn M Drewes; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  United European Gastroenterol J       Date:  2020-05-09       Impact factor: 4.623

3.  Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum.

Authors:  D L Sigalet; O Bawazir; G R Martin; L E Wallace; G Zaharko; A Miller; A Zubaidi
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

Review 4.  Nutritional and pharmacological strategy in children with short bowel syndrome.

Authors:  Michael E Höllwarth; Valeria Solari
Journal:  Pediatr Surg Int       Date:  2021-01-03       Impact factor: 1.827

5.  Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats.

Authors:  Takuya Inoue; Masaaki Higashiyama; Izumi Kaji; Sergiy Rudenkyy; Kazuhide Higuchi; Paul H Guth; Eli Engel; Jonathan D Kaunitz; Yasutada Akiba
Journal:  Dig Dis Sci       Date:  2013-12-31       Impact factor: 3.199

Review 6.  Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.

Authors:  Chinmay S Marathe; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Exp Diabetes Res       Date:  2011-06-22

7.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.